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Abstract
Acute and chronic complications from the substituted amphetamine 3,4-
methylenedioxymethamphetamine (MDMA) are linked to activation of the hypothalamic-
pituitary-adrenal (HPA) axis. How MDMA activates the HPA axis is not known. HPA responses
to stress are known to be mediated through the paraventricular (PVH) hypothalamus and to
involve serotonin-1a (5-HT1A) receptors. We sought to determine if the PVH and 5-HT1A
receptors were also involved in mediating HPA responses to MDMA. Rats were pretreated with
either saline or a 5-HT1A antagonist, WAY-100635 (WAY), followed by a systemic dose of
MDMA (7.5 mg/kg i.v.). Animals pretreated with WAY had significantly lower plasma ACTH
concentrations after MDMA. To determine if neurons in the PVH were involved, and if their
involvement was mediated by 5-HT1A receptors, rats implanted with guide cannulas targeting the
PVH were microinjected with the GABAA receptor agonist muscimol, aCSF, or WAY followed
by MDMA. Compared to aCSF microinjections of muscimol significantly attenuated the MDMA-
induced rise in plasma ACTH (126 vs. 588 pg/ml, P=<0.01). WAY had no effect. Our data
demonstrates that neurons in the PVH, independent of 5-HT1A receptors, mediate ACTH
responses to MDMA.
Introduction
In humans and laboratory animals, MDMA activates the hypothalamic-pituitary-adrenal
(HPA) axis thus increasing circulating concentrations of adrenocorticotropic hormone
(ACTH) and corticosteroids [11, 29]. This activation has been linked to both acute and
chronic complications. Acutely, corticosteroids facilitate the development of hyperthermia
from MDMA. Rats which have had their adrenal or pituitary removed fail to develop, or
have attenuated, hyperthermia [7, 38]. Alterations in the function of the HPA axis are also
associated with chronic complications from MDMA. Compared to drug-naive subjects,
habitual MDMA users have higher basal plasma ACTH concentrations and blunted stress
responses [8]. Similar effects have been reported in persons with clinical depression and
anxiety [19] linking the HPA axis to psychiatric problems in heavy MDMA users [26].
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Despite a connection between the HPA axis and its complications, how MDMA activates
the HPA axis is not known. Experimental stress activates the HPA axis similar to that seen
with MDMA [5]. These responses are suppressed, or prevented, by inhibiting neurons in the
region the paraventricular hypothalamus (PVH)[5]. 5-HT1A receptors are also linked to
stress responses: blocking 5-HT1A receptors, through systemic or intracerebral
administration of 5-HT1A antagonists, reduces increase in ACTH from restraint stress [21,
22].
The PVH and 5-HT1A receptors may also play a role in MDMA’s ACTH responses.
MDMA is a potent serotonin releaser and activates neurons in the PVH [12, 14].
Furthermore, microinjecting, or perfusing, 5-HT1A agonists into the PVH increases plasma
ACTH concentrations [2, 31, 32] and conversely, microinjections of the 5-HT1A antagonist
WAY-100635 (WAY) into the PVH inhibit plasma ACTH increases evoked by the systemic
administration of 8-OH-DPAT [31]. Based on this, we hypothesized that 5-HT1A receptors
in the PVH were involved in ACTH responses to MDMA.
Materials and Methods
Animals
Male Sprague-Dawley rats (weight 300 ± 20 g; Harlan, Indianapolis, IN) were singly
housed, maintained in a 12 h light/dark cycle beginning at 7 a.m, and fed ad libitum.
Experiments were conducted in isolated rooms between 10:00 a.m. and 2:00 p.m. Animals
were acclimated to the experimental rooms for a minimum of 2 h before experiments. Care
and use of rats was approved by the Indiana University Animal Care and Use Committee.
Chemicals
MDMA, generously provided by the NIH, was dissolved the day of the experiment in
normal saline; injection volumes were 1 ml/kg body weight. Muscimol (Sigma-Aldrich, St.
Louis, MO) was dissolved in artificial CSF (aCSF) and stored at −20°C until the time of the
experiment. WAY (Sigma-Aldrich) was dissolved in sterile saline and used fresh or stored
until use at −20°C.
Surgical preparation
Animals were anaesthetized with a ketamine/xylazine cocktail (80 mg/kg ketamine; 11.5
mg/kg xylazine, i.p.), with supplemental doses provided as needed, femoral artery (for blood
withdrawal) and venous (for drug administration) catheters were inserted as previously
described [1, 36]. For experiments involving microinjections, animals were placed in a
stereotaxic apparatus and bilateral microinjection guide cannulas (26 gauge, Plastics One,
Roanoke, VA) were positioned into the region of the PVH using the following coordinates:
incisor bar 5 mm above the interaural line, 10 degree angle from the sagittal plane, AP 0.0
mm; LR ±2.1 mm; HD −7.3 mm. Once inserted, cannulas were secured with stainless steel
screws, Vetbond glue (3M, St. Paul, MN) and cranioplastic cement. Dummy-wire cannulas
were inserted in the guides, and the rats returned to their home cages for a minimum of
seven days.
ACTH Measurement
Blood (0.35 ml) was withdrawn from arterial catheters and replaced with an equal volume of
sterile saline. The syringes used for blood draws contained 60 μl of a solution containing 10
mg/ml EDTA and 50% aprotinin. Samples were immediately transferred to 0.5 ml
Eppendorf tubes, and centrifuged at 12,100 g for 26 sec in a MiniSpin centrifuge
(Eppendorf, Hamburg, Germany) to separate the plasma. Samples were stored at −80°C
until analyzed.
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Plasma ACTH concentrations were determined by RIA using a modification of a previously
reported method [43]. This double antibody assay uses a rabbit antiserum (IgG Corp,
Nashville, TN) recognizing the ACTH5-18, and goat anti-rabbit globulin (EMD Millipore,
Billerica, MA) to precipitate the antigen antibody complex. ACTH for RIA standards was
from Bachem (Torrance, CA), and 125I-ACTH from Diasorin Inc (Stillwater, MN). Counts
were recorded on a gamma counter (Cobra II, Perkin Elmer, Watham, MA) and duplicate
standard curves were used.
Experimental Protocols
Time Course of ACTH after MDMA
We determined peak plasma concentrations of ACTH by taking blood samples from rats
(n=4) 5 min before and 15, 30, 60, 120, and 180 min after an i.v. dose of MDMA (7.5 mg/
kg). This MDMA dose causes temperature and cardiovascular responses mimicking those
seen in human intoxication, results in plasma concentrations similar to humans taking
recreational doses [10], and, microinjections of muscimol into the region of the DMH (a
brain region associated with sympathetic responses to MDMA) attenuated temperature,
cardiovascular, and behavioral responses produced by this dose [36]. Since intraperitoneal
injections cause stress responses—including increases in plasma ACTH concentrations [27]
—drugs were injected intravenously.
The effect of a systemic dose of WAY on MDMA-induced increases in plasma ACTH
To determine WAYs effects on plasma ACTH after MDMA, rats (n=4) were pretreated
(i.v.) with equal volumes of vehicle (0.9% NaCl) or WAY (0.5 mg/kg) followed 5 min later
by MDMA (7.5 mg/kg). After a 2-day washout animals were crossed-over to receive the
other pretreatment followed by MDMA; the order of administration was random. Blood was
withdrawn 5 min before WAY or saline and 15 min after MDMA. The WAY dose was the
same we previously showed decreases MDMA locomotion [35] and prevents increases in
plasma ACTH produced by the 5-HT1A agonist 8-OH-DPAT [41]. Although 8-OH-DPAT is
both a 5-HT1A and 5-HT7 agonist, only its 1A effects are linked to ACTH secretion[6]. Like
many drugs WAY is selective but not specific for certain receptors. At high doses WAY
antagonizes dopamine-4 (D4) receptors [25], however the concentration we used how is
below that shown to block D4 receptors in vivo [25]
Effect of muscimol or WAY microinjections on increases in plasma ACTH produced by
MDMA
To investigate whether the PVH, and more specifically 5-HT1A receptors in the PVH, play a
role in endocrine responses to MDMA, we conducted the following experiment. Rats were
acclimated to their cage (Raturn®, Basi, Layfayette IN) overnight. Then, microinjectors (33
gauge, Plastics One) were connected to a 10 μl Hamilton syringe with Teflon tubing (ID
0.12 mm; OD 0.65 mm; BASi). The syringe was mounted on an infusion pump (Model 200,
KD Scientific, Holliston, MA) to microinject either 100 nL of aCSF, muscimol (80 pmol),
or WAY (0.5 nmol). Muscimol, a GABAA agonist, was used to suppress neuronal activity in
the PVH where it has been shown to hyperpolarize neurons [16]. The dose used has been
shown to decrease ACTH concentrations caused by stress [40]. The dose of WAY was the
same we have previously shown prevents hypothermia, when microinjected into the
medullary raphe pallidus, from a systemic dose of 8-OH-DPAT [35]. Solutions contained
0.25% fluorescent microspheres (0.04 μm in diameter; Invitrogen, Carlsbad, CA) to mark
the injection site. Since placing microinjectors evokes a mild stress response, animals were
left undisturbed for at least 1 h after the injectors were placed [44]. Blood was withdrawn to
obtain baseline ACTH concentrations, then 5 min later animals were microinjected, over 30
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seconds, with muscimol, WAY, or aCSF and five min later MDMA (7.5 mg i.v.) was
injected.
Verification of microinjections
At the conclusion of each experiment rats were injected with pentobarbital (100 mg/kg, i.v.)
and transcardially perfused with 30 ml of cold saline (4°C) followed by 30 ml of 4%
paraformaldehyde. Brains were removed and placed overnight (at 4°C) in 4% solution of
paraformaldehyde and afterwards stored in a 30% sucrose solution until processed.
Using a cryostat (Leica Microsystems, Buffalo Grove, IL) 40 μm coronal brain sections
were cut and microsphere location was determined using a fluorescent microscope according
to the atlas of Paxinos and Watson (47) by an observer blinded to group allocation.
Data Analysis and Statistical Procedures
Statistics and graphs were generated using Prism (Graphpad Software, San Diego, CA)
software. ACTH was reported as change from baseline. In the time course experiment we
ran a repeat measures ANOVA test with a Dunnett’s post-hoc test comparing each value to
baseline. Experiments with systemic WAY were analyzed using a paired Student t-test and
microinjection experiments analyzed by ANOVA with a Tukey’s HSD post-hoc analysis. In
all of these experiments significance was defined as a P-value <0.05.
Results
ACTH Time course andthe effect of systemic WAY
An i.v. dose of MDMA caused a rapid increase in plasma ACTH concentrations (Fig. 1A).
Peak concentrations occurred at 15 min and were >1000% above baseline. Mean baseline
and peak ACTH concentrations (± 1 SEM) were 72 (±11) and 893 (±167) pg/ml
respectively.
WAY (0.5 mg/kg, i.v.) significantly decreased plasma ACTH concentrations evoked by
MDMA (Fig 1B). Mean increases in ACTH (± 1SEM) in the WAY and Saline groups were
198 (±52) and 642 (±66) pg/ml respectively. Mean baseline concentrations (± 1SEM) for the
WAY and saline groups were 55 (±6) and 66 (±15) pg/ml.
Microinjection sites
Microinjection sites were confirmed by fluorescent microspheres as demonstrated in the
representative brain section (Fig. 2A). The approximate centers of each microinjection were
elucidated from the corresponding H&E stained section (Fig. 2B) and plotted on schematic
coronal sections in which the PVH was demarcated using drawings adapted from the atlas of
Paxinos and Watson [33]. The total area encompassing all the injections for the PVH is
shown in gray (2C). Injection sites extended in this region so that correct locations were
attributed to injections between −1.8 to −2.12 mm (from bregma) in the region of PVH.
Effect of muscimol or WAY microinjections on increases in plasma ACTH produced by
MDMA
Compared to aCSF, microinjections of muscimol into the PVH, but not WAY, significantly
reduced increases in plasma ACTH evoked by MDMA (Fig. 3). There were no differences
in mean baseline concentrations between aCSF (65±17 pg/ml), muscimol (57±17 pg/ml), or
WAY (74±21 pg/ml) respectively. We have previously shown that microinjections of
muscimol or aCSF do not by themselves significantly increase ACTH [1]. It is not known
however whether microinjections of WAY into the region of the PVH affect ACTH
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concentrations, therefore, we conducted an additional experiment microinjecting either
aCSF or WAY into the PVH followed by a systemic dose of saline (n=4/group). There were
no differences in mean change in plasma ACTH (48±8 pg/ml v 43±8 pg/ml, p=0.4) or in
baseline ACTH concentrations (50±7 pg/ml v 32±13 pg/ml).
Discussion
Our results show that 5-HT1A receptors and neurons in the region of the PVH are involved
in HPA activation produced by MDMA, but that the location of the involved 5-HT1A
receptors is outside of the PVH.
Serotonin receptors are known to regulate plasma ACTH concentrations [23], and drugs that
activate either 5-HT1A [18, 21, 23] or 5-HT2A [18, 34] receptors increase circulating
concentrations of ACTH. A potent releaser of serotonin, MDMA has effects on body
temperature that are thought to involve 5-HT1A and 5-HT2A receptors [15, 30]. Both
receptors could mediate the neuroendocrine effects of MDMA. 5-HT1A agonists (i.e., 8-OH-
DPAT) cause increase in ACTH concentrations that closely parallel those seen with MDMA
(Fig. 1A) [18]. While we confirmed a role for 5-HT1A receptors in ACTH responses to
MDMA, our findings do not eliminate the additional involvement of 5-HT2A receptors. In
support of this, systemic injections of WAY reduce but do not abolish MDMA-induced
increases in plasma ACTH (Fig. 1B). Data from Nash et al. supports a role for 5-HT2A
receptors as they showed that ketanserin and mianserin, at relatively high doses, decreased
corticosterone concentrations after MDMA [29]. While both drugs antagonize 5-HT2A
receptors they also antagonize other monoaminergic receptors including alpha-1 receptors,
which are linked to hypothalamic control of ACTH secretion [20]. Nash’s study also seems
to conflict with our WAY experiments. They reported that pindolol, a 5-HT1A antagonist,
did not prevent MDMA-induced increases in corticosterone [29]. Pindolol, however, has
been shown to be a mixed 5-HT1A agonist-antagonist [17], exhibiting both agonist [4, 39]
and antagonist [13, 42] properties depending on dose and local serotonin concentrations.
Nash used a dose of pindolol (0.3 mg/kg) below that shown to have 5-HT1A antagonist
properties [13, 42].
The finding that the PVH was involved in MDMA-mediated ACTH responses suggests that
MDMA activates neurons in the PVH—the primary site of corticotropin-releasing hormone
synthesis[24]. Previous work has shown that 5-HT1A receptors in the PVH mediate ACTH
responses to both systemically and centrally administered 5-HT1A agonists [2, 31, 32].
When viewed in this light, we were surprised to find that 5-HT1A receptors in the PVH did
not mediate ACTH responses from MDMA. One possible explanation for this is that we
microinjected insufficient concentration of WAY effectively block 5-HT1A receptors. This
however is unlikely as the dose of WAY was the same as that which when microinjected
into the medullary raphe pallidus prevents hypothermia induced by a systemic dose of 8-
OH-DPAT [35]. Rather, we suggest that the location(s) of 5-HT1A receptors involved in
MDMA-mediated effects on plasma ACTH are upstream of the PVH. There are numerous
potential sites that send efferents to the PVH and which contain, or are known to be
influenced by 5-HT1A receptors: e.g., dorsal raphe nucleus, the bed nucleus of the stria
terminalis, the preoptic area of the hypothalamus, and the amygdala [9, 22, 37]. Many of
these sites are also known to send GABAergic projections to the PVH [28], such that
through the release of 5-HT, MDMA could disinhibit CRH neurons in the PVH. Any of
these, or numerous other, sites could be involved. Another possibility is that WAY acted on
5-HT1A receptors at the level of the pituitary [3]. Since our data showed nearly complete
suppression (78%) when the PVH was inhibited we think this possibility is unlikely. Further
work is needed to determine the site and mechanism of WAY’s action on increases in
plasma ACTH seen after administration of MDMA.
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In conclusion, we have shown that neurons in the PVH are involved in to the activation of
the HPA axis mediated by the substituted amphetamine MDMA. Furthermore we have
shown that 5-HT1A receptors outside of the PVH are involved. Understanding how the HPA
axis is activated by MDMA and other amphetamines may shed light on the mechanisms
behind their acute and chronic complications.
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Highlights
• MDMA increases plasma ACTH levels
• Systemic WAY-100635 prevents these ACTH increases
• Inhibiting of neurons in the PVH also prevents these ACTH increases
• Microinjections of WAY-100635 into the PVH do not prevent ACTH increases
• Activation of HPA axis by MDMA separately involves 5-HT1a receptors and
PVH neurons
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Fig 1.
Fig. 1A. Intravenous injection of MDMA causes a rapid and significant rise in ACTH.
Circles represent mean ACTH concentrations and correspond to the time points when blood
was withdrawn for measurement (−10, 15, 30, 60, 120, and 180 min). Error bars represent 1
SEM. *Represent significant difference compared to baseline ACTH concentrations as
determined by repeat measures ANOVA with a Dunnett’s post hoc analysis. Fig. 1B. A
systemic dose of WAY attenuates increases in ACTH produced by MDMA. Vertical
rectangular bars, and their corresponding numbers, represent the mean change in plasma
ACTH after a dose of MDMA (7.5 mg/kg) for animals previously injected with WAY (0.5
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mg/kg, i.v.) or saline. Error bars represent 1 SEM. The P-value for comparison between the
WAY and Saline groups is represented (paired t-test).
Zaretsky et al. Page 11
Neurosci Lett. Author manuscript; available in PMC 2014 October 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Injection sites. Figure A and B show the injection site of a single, representative, animal.
The distribution of green fluorescent microspheres (A) marks the sites of a muscimol
injection into the region of PVH. The neutral red counterstained section (B) shows the
anatomic landmarks used for marking the injection sites. Figure 3C is a schematic, adapted
from the atlas of Paxions and Watson [33], summarizing the microinjection sites for studies
employing muscimol, WAY, and aCSF. The gray schematic in each figure represents the
cumulative spread of fluorescent microspheres co-microinjected with drug or aCSF. Each
region shown is a representative; injections may have extended anteriorly or posteriorly by
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no more than 0.5 mm. Abbreviations: PVH=paraventricular hypothalamus, f=fornix, 3V=3rd
ventricle.
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Fig. 3.
The effect of microinjections of muscimol, WAY, or aCSF into the PVH on MDMA-
mediated increases in ACTH: Vertical rectangular bars and their corresponding numbers
represent the mean change in plasma ACTH after a dose of MDMA (7.5 mg/kg) in animals
previously microinjected into the PVH, with either aCSF, muscimol (80 pmol/100nl) or
WAY (0.5 nmol/100nl). Error bars represent 1 SEM. The number of animals in each group
is noted by the number at the base of each vertical rectangular bar. P-values were calculated
using ANOVA with a Tukey’s HSD post hoc analysis.
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